News
KURA
10.26
-2.84%
-0.30
Bank of America Securities Remains a Buy on Kura Oncology (KURA)
TipRanks · 1d ago
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA)
TipRanks · 2d ago
Weekly Report: what happened at KURA last week (1019-1023)?
Weekly Report · 5d ago
Weekly Report: what happened at KURA last week (1012-1016)?
Weekly Report · 10/19 09:24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ramsay Health Care (OtherRMSYF), PTC Therapeutics (PTCT) and Kura Oncology (KURA)
TipRanks · 10/14 12:30
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Alnylam Pharma (ALNY) and Kura Oncology (KURA)
TipRanks · 10/14 11:10
Caspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246
NASDAQ · 10/13 14:30
Kura Oncology, Caspian outline KO-7246 development strategy in diabetes
TipRanks · 10/13 13:21
Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
Benzinga · 10/13 11:31
Weekly Report: what happened at KURA last week (1005-1009)?
Weekly Report · 10/12 09:26
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Barchart · 10/07 06:15
Weekly Report: what happened at KURA last week (0928-1002)?
Weekly Report · 10/05 09:26
Qifu, Cracker Barrel, Cemex, Kura, Photronics Insider Shock
TipRanks · 10/03 13:01
Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 10/02 11:30
This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 10/01 16:03
Kura Oncology Price Target Announced at $30.00/Share by JP Morgan
Dow Jones · 10/01 14:55
Kura Oncology Initiated at Overweight by JP Morgan
Dow Jones · 10/01 14:55
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
Benzinga · 10/01 14:45
Kura Oncology initiated with an Overweight at JPMorgan
TipRanks · 10/01 08:45
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and AbbVie (ABBV)
TipRanks · 10/01 05:20
More
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.